Raymond James Financial Services Advisors’s CASI Pharmaceuticals CASI Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,009	Closed	-$242K	–	2809
2018 Q4	$242K	Buy	6,009 +2,200	+58%	+$83.3K	﹤0.01%	2137
2018 Q3	$178K	Sell	3,809 -1,400	-27%	-$97.7K	﹤0.01%	2565
2018 Q2	$429K	Hold	5,209	–	–	﹤0.01%	1975
2018 Q1	$217K	Buy	5,209 +3,200	+159%	+$119K	﹤0.01%	2207
2017 Q4	$65K	Sell	2,009 -3,505	-64%	-$95.2K	﹤0.01%	2422
2017 Q3	$98K	Hold	5,514	–	–	﹤0.01%	2393
2017 Q2	$58K	Buy	5,514 +5	+0.1%	+$53	﹤0.01%	2399
2017 Q1	$78K	Hold	5,509	–	–	﹤0.01%	2285
2016 Q4	$63K	Hold	5,509	–	–	﹤0.01%	2222
2016 Q3	$61K	Sell	5,509 -3	-0.1%	-$33	﹤0.01%	2190
2016 Q2	$64K	Hold	5,512	–	–	﹤0.01%	2153
2016 Q1	$58K	Buy	+5,512	New	+$53.4K	﹤0.01%	1953

Other funds holding CASI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James Financial Services Advisors's CASI Position: Q1 2019 in Review

Raymond James Financial Services Advisors sold out of CASI Pharmaceuticals (CASI) in Q1 2019, closing a stake of 6,009 shares — an estimated $242K sold.

Raymond James Financial Services Advisors first reported a position in CASI in Q1 2016 and held it in 12 quarters. The position peaked at $429K in Q2 2018. 52 funds tracked by Wall St. Rank hold CASI as of Q1 2019.

Raymond James Financial Services Advisors reported no remaining CASI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 6,009 CASI Pharmaceuticals shares in Q1 2019, an estimated $242K.
Raymond James Financial Services Advisors first reported a position in CASI Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Raymond James Financial Services Advisors's CASI Pharmaceuticals position peaked at $429K in Q2 2018.
52 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2019, filed 6 May 2019.